|By PR Newswire||
|April 15, 2014 04:05 AM EDT||
LONDON, April 15, 2014 /PRNewswire/ --
reViral, an antiviral drug discovery and development company, focused on diseases caused by the respiratory syncytial virus (RSV), today announced the appointment of Professor Raymond Schinazi to its Board as a Non-Executive Director, effective from 9 April 2014.
Professor Schinazi has had a long and prestigious career in the industry having founded several successful biotechnology companies including Pharmasset, where he chaired the Board and directed the scientific research that lead to the discovery of Solvadi, a curative drug for hepatitis C virus infections, as well as previously commercialising inventions that have revenues of over $2 billion per year.
Ken Powell, Chairman and Founder of reViral, commented on the appointment: "We are very pleased to have attracted someone of Ray's experience and prestige to reViral. A world leader in nucleoside chemistry and biology, Ray's discoveries have made a tangible impact on the quality of life and welfare of society. His remarkable accomplishments and wealth of experience will be integral to reViral as the company grows to become a leader in the antiviral space."
Professor Schinazi, newly appointed Non-Executive Director of reViral said: "reViral is at the forefront of RSV treatments, developing novel first-in-class compounds that have the potential to revitalise and transform the market. I look forward to working with the proven management team and am excited by the Company's highly promising programme and pipeline, as it expands into areas of high unmet need."
Khatereh Ahmadi, Chief Executive Officer and Founder of reViral added: "The lack of treatment options for RSV and limited competition offers a significant market for innovative therapies like ours. Professor Schinazi's track record will be invaluable to reViral as we look to bring our novel treatments for RSV to the market place, selecting a preclinical candidate this year and entering IND enabling studies in 2015."
reViral has developed a novel series of antiviral inhibitors targeting RSV fusion - including its lead compound (RV521) - which is highly potent and orally bioavailable with strong drug like characteristics. RSV is the most important respiratory pathogen with 64 million infections and as many as 200,000 deaths worldwide annually in children under 5 years alone. There are currently no RSV vaccines available and there is an urgent need for improved drugs for this indication.
Professor Schinazi holds a Bachelor of Science, a Ph.D. and received an Honorary Doctor of Science degree for his research accomplishments in the field of HIV and biotechnology from the University of Bath, England, and completed postdoctoral training in Pharmacology at Yale University and in Virology/Immunology from Emory University.
NOTES TO EDITORS
About Professor Schinazi
Professor Schinazi is the Frances Winship Walters Professor of Pediatrics and Director of the Laboratory of Biochemical Pharmacology at Emory University. He serves as Senior Research Career Scientist at the Atlanta Department of Veterans Affairs and Director of the Scientific Working Group on Viral Eradication for the NIH-sponsored Emory University Center for AIDS Research (CFAR). Dr. Schinazi received his BSc (1972) and PhD (1976) in chemistry from the University of Bath, England. He has authored over 500 peer-reviewed papers and 7 books and holds 92 issued U.S. patents and over 120 non-U.S. national stage patents and patent applications, which have resulted in 12 New Drug Applications (NDA). A world leader in nucleoside chemistry, Dr. Schinazi is best known for his pioneering work on HIV and HCV drugs d4T (stavudine), 3TC (lamivudine), FTC (emtricitabine/Emtriva), LdT (telbivudine), and most recently sofosbuvir (Sovaldi), which are now approved by the FDA. He is also the founder of five biotechnology companies including Pharmasset, Inc. (VRUS; acquired by Gilead in 2012 for 11.4 B). More than 94% of HIV-infected individuals in the US on combination therapy take at least one of the drugs he invented, and it is estimated that his work has saved more than 3 million lives worldwide. His contributions related to HCV are expected to have a profound positive impact on the approximately 170 million people worldwide suffering from chronic infection. Dr. Schinazi served on the Presidential Commission on AIDS and is the recipient of numerous awards including the 2006 Distinguished Scientist Award from the Hepatitis B Foundation, the Friends of the National Library of Medicine 2013 Distinguished Medical Science Award, and the SCRIP "100 Leaders" Award in 2014. He was also chosen in 2011 as one of Emory University's "175 History Makers." He currently serves as a Governing Trustee for the Foundation for AIDS Research (amfAR). He was inducted into the Technology Hall of Fame of Georgia in March 2012, received the Intellectual Property Legends Award in October 2012, and was inducted into the National Academy of Inventors as a Charter Fellow in January 2013. Dr. Schinazi is internationally recognized as one of the most influential persons in the life science sector.
ReViral is an antiviral drug discovery and development company, focused on novel antiviral treatments for diseases caused by the respiratory syncytial virus (RSV).
Founded in 2011, reViral has an experienced R&D leadership team with a successful track record in antiviral drug discovery and development. The company has developed a novel antiviral program targeting RSV fusion with highly potent, orally bioavailable inhibitors with strong drug like characteristics and good pharmacokinetic properties offering versatility in route of administration. In 2012 reViral won a significant Seeding Drug Discovery Initiative Award from the Wellcome Trust to develop its RSV fusion inhibitors to completion of IND filing. The company also has an RSV replication program at an earlier stage of development and plans to expand its pipeline in other antivirals for diseases with a high unmet need.
About Human Respiratory Syncytial Virus (RSV)
Human Respiratory Syncytial Virus (RSV) is the most important respiratory pathogen, responsible for one-fifth of all lower respiratory tract infections worldwide. Historically it has been considered to be solely an infection of children, however, with the ever-increasing awareness of diseases of the elderly and immunocompromised patient populations this perception is changing.
RSV infection is responsible for more infant hospitalizations than other viral infections such as influenza. Susceptible populations are premature infants, children, transplant patients, the elderly and people of all ages with heart failure and lung disease. In addition, severe infection in infancy is linked to the later development of asthma. In the elderly in the US it was shown that RSV infection caused 177,500 hospital admissions and 14,000 deaths over a period of 4 years. Hospitalization costs alone were estimated at more than $1 billion.
WebRTC is about the data channel as much as about video and audio conferencing. However, basically all commercial WebRTC applications have been built with a focus on audio and video. The handling of “data” has been limited to text chat and file download – all other data sharing seems to end with screensharing. What is holding back a more intensive use of peer-to-peer data? In her session at @ThingsExpo, Dr Silvia Pfeiffer, WebRTC Applications Team Lead at National ICT Australia, will look at di...
Oct. 7, 2015 11:30 AM EDT Reads: 515
Saviynt Inc. has announced the availability of the next release of Saviynt for AWS. The comprehensive security and compliance solution provides a Command-and-Control center to gain visibility into risks in AWS, enforce real-time protection of critical workloads as well as data and automate access life-cycle governance. The solution enables AWS customers to meet their compliance mandates such as ITAR, SOX, PCI, etc. by including an extensive risk and controls library to detect known threats and b...
Oct. 7, 2015 11:15 AM EDT
SYS-CON Events announced today that Luxoft Holding, Inc., a leading provider of software development services and innovative IT solutions, has been named “Bronze Sponsor” of SYS-CON's @ThingsExpo, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Luxoft’s software development services consist of core and mission-critical custom software development and support, product engineering and testing, and technology consulting.
Oct. 7, 2015 11:15 AM EDT Reads: 568
Culture is the most important ingredient of DevOps. The challenge for most organizations is defining and communicating a vision of beneficial DevOps culture for their organizations, and then facilitating the changes needed to achieve that. Often this comes down to an ability to provide true leadership. As a CIO, are your direct reports IT managers or are they IT leaders? The hard truth is that many IT managers have risen through the ranks based on their technical skills, not their leadership ab...
Oct. 7, 2015 11:00 AM EDT Reads: 854
Learn how Backup as a Service can help your customer base protect their data. In his session at 17th Cloud Expo, Stefaan Vervaet, Director of Strategic Alliances at HGST, will discuss the challenges of data protection in an era of exploding storage requirements, show you the benefits of a backup service for your cloud customers, and explain how the HGST Active Archive and CommVault are already enabling this service today with customer examples.
Oct. 7, 2015 11:00 AM EDT Reads: 681
For almost two decades, businesses have discovered great opportunities to engage with customers and even expand revenue through digital systems, including web and mobile applications. Yet, even now, the conversation between the business and the technologists that deliver these systems is strained, in large part due to misaligned objectives. In his session at DevOps Summit, James Urquhart, Senior Vice President of Performance Analytics at SOASTA, Inc., will discuss how measuring user outcomes –...
Oct. 7, 2015 11:00 AM EDT Reads: 406
As a company adopts a DevOps approach to software development, what are key things that both the Dev and Ops side of the business must keep in mind to ensure effective continuous delivery? In his session at DevOps Summit, Mark Hydar, Head of DevOps, Ericsson TV Platforms, will share best practices and provide helpful tips for Ops teams to adopt an open line of communication with the development side of the house to ensure success between the two sides.
Oct. 7, 2015 11:00 AM EDT Reads: 555
The enterprise is being consumerized, and the consumer is being enterprised. Moore's Law does not matter anymore, the future belongs to business virtualization powered by invisible service architecture, powered by hyperscale and hyperconvergence, and facilitated by vertical streaming and horizontal scaling and consolidation. Both buyers and sellers want instant results, and from paperwork to paperless to mindless is the ultimate goal for any seamless transaction. The sweetest sweet spot in innov...
Oct. 7, 2015 11:00 AM EDT Reads: 144
Clutch is now a Docker Authorized Consulting Partner, having completed Docker's certification course on the "Docker Accelerator for CI Engagements." More info about Clutch's success implementing Docker can be found here. Docker is an open platform for developers and system administrators to build, ship and run distributed applications. With Docker, IT organizations shrink application delivery from months to minutes, frictionlessly move workloads between data centers and the cloud and achieve 2...
Oct. 7, 2015 10:45 AM EDT Reads: 459
There are so many tools and techniques for data analytics that even for a data scientist the choices, possible systems, and even the types of data can be daunting. In his session at @ThingsExpo, Chris Harrold, Global CTO for Big Data Solutions for EMC Corporation, will show how to perform a simple, but meaningful analysis of social sentiment data using freely available tools that take only minutes to download and install. Participants will get the download information, scripts, and complete en...
Oct. 7, 2015 10:21 AM EDT
“All our customers are looking at the cloud ecosystem as an important part of their overall product strategy. Some see it evolve as a multi-cloud / hybrid cloud strategy, while others are embracing all forms of cloud offerings like PaaS, IaaS and SaaS in their solutions,” noted Suhas Joshi, Vice President – Technology, at Harbinger Group, in this exclusive Q&A with Cloud Expo Conference Chair Roger Strukhoff.
Oct. 7, 2015 10:00 AM EDT Reads: 374
SYS-CON Events announced today that Interface Masters Technologies, provider of leading network visibility and monitoring solutions, will exhibit at the 17th International CloudExpo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Interface Masters Technologies is a leading provider of high speed networking solutions focused on Gigabit, 10 Gigabit, 40 Gigabit and 100 Gigabit Ethernet network access and connectivity products. For over 20 ye...
Oct. 7, 2015 10:00 AM EDT Reads: 672
Redis is not only the fastest database, but it has become the most popular among the new wave of applications running in containers. Redis speeds up just about every data interaction between your users or operational systems. In his session at 17th Cloud Expo, Dave Nielsen, Developer Relations at Redis Labs, will share the functions and data structures used to solve everyday use cases that are driving Redis' popularity
Oct. 7, 2015 10:00 AM EDT Reads: 457
SYS-CON Events announced today that Secure Infrastructure & Services will exhibit at SYS-CON's 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Secure Infrastructure & Services (SIAS) is a managed services provider of cloud computing solutions for the IBM Power Systems market. The company helps mid-market firms built on IBM hardware platforms to deploy new levels of reliable and cost-effective computing and hig...
Oct. 7, 2015 10:00 AM EDT Reads: 791
SYS-CON Events announced today that Harbinger Systems will exhibit at SYS-CON's 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Harbinger Systems is a global company providing software technology services. Since 1990, Harbinger has developed a strong customer base worldwide. Its customers include software product companies ranging from hi-tech start-ups in Silicon Valley to leading product companies in the US a...
Oct. 7, 2015 10:00 AM EDT Reads: 758